Verrica Says $15 Million Credit Commitment Could Extend Runway Into Q4 2027

Verrica Pharmaceuticals Inc. said its remaining $15 million credit commitment could extend its cash runway into the fourth quarter of 2027, beyond expected results from two common-warts trials of YCANTH.

The company expects top-line results from COVE-2 in the first quarter of 2027, followed by COVE-3 data by midyear. The credit commitment could carry its runway past both anticipated readouts.

Verrica also reported a second consecutive quarterly revenue record for YCANTH. The company cited improved yield per prescription after it directed medical-benefit claims to in-network pharmacies, while noting seasonal effects on unit volume.

The next expected trial update is top-line COVE-2 data in the first quarter of 2027.